37th ACS National Medicinal Chemistry Symposium

American Chemical Society
Division of Medicinal Chemistry

 New York City, NY, United States    June 27-30, 2021

Scientific Program


10:00 am

Registration

Welcome Address by NMCS NYC 2020 Co-Chairs

01:00 pm

Dr Amjad ALI
MERCK & CO. INC., Kenilworth, United States
Prof. Robert DEVITA
ICAHN SCHOOL OF MEDICINE AT MT. SINAI, New York, United States

Session 1: Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery

01:15 pm

Introduction by Session Chair

Dr Maria-Jesus BLANCO
SAGE THERAPEUTICS, Cambridge, United States

01:20 pm

Protein Degradation beyond Oncology

Dr Nello MAINOLFI
KYMERA THERAPEUTICS, Cambridge, United States

01:50 pm

Integrating DNA-Encoded Library Technologies in Lead Discovery

Dr Lisa MARCAURELLE
GSK, Cambridge, United States

02:20 pm

Translating RNA Sequence into Lead Small Molecule Medicines

Prof. Matthew DISNEY
SCRIPPS RESEARCH INSTITUTE, Jupiter, United States

02:50 pm

Coffee Break & Exhibition

03:20 pm

Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets

Prof. Kyle HADDEN
UNIVERSITY OF CONNECTICUT, Storrs, United States

03:50 pm

Discovery and Development of Macrocyclic Peptides for the Treatment of Complement-Mediated Disorders

Dr Susan ASHWELL
RA PHARMA, Cambridge, United States

04:20 pm

Impact of Structure Based Drug Design in GPCR Lead Optimisation Strategies

Dr Miles CONGREVE
SOSEI HEPTARES, Welwyn Garden City, United Kingdom

04:50 pm

Free Time

06:00 pm

Welcome Reception & Networking

07:00 pm

End of the Day

Session 2: New Directions in Targeting DNA Damage Repair (DDR)

08:30 am

Introduction by Session Chairs

Dr Erin DIMAURO
MERCK & CO. INC., Boston, United States
Dr Srinivasa KARRA
NOT EMPLOYED, Pembroke, United States

08:35 am

Damage Incorporated: Discovery of ATR Inhibitor BAY 1895344 with Favorable PK Properties and Promising Anti-Tumor Efficacy in Monotherapy and Combination in Preclinical Tumor Models

Dr Ulrich LÜCKING
BAYER AG, Berlin, Germany

09:05 am

Discovery and Optimization of Novel PARG Inhibitors

Dr Hilary BECK
IDEAYA BIOSCIENCES, SOUTH SAN FRANCISCO, United States

09:35 am

The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response

Prof. Phil REIGAN
UNIVERSITY OF COLORADO, Aurora, United States

10:05 am

Coffee Break & Exhibition

10:35 am

M3541 and M4076: Discovery and Optimization of Potent and Selective ATM Kinase Inhibitors with Strong Anti-tumor Efficacy in Combination Therapies

Dr Thomas FUCHSS
MERCK KGAA - MERCK BIOPHARMA, Darmstadt, Germany

11:05 am

Discovery of DNA Polymerase theta (Polθ) Inhibitors: HTS to in vitro Probes

Dr Robert HEALD
ARTIOS PHARMA LTD, Cambridge, United Kingdom

11:35 am

Discovery of Potent and Selective DNA-PK Inhibitors via Structure-Guided Virtual Screening Strategies

Dr Charlene FALLAN
ASTRAZENECA, Cambridge, United Kingdom

12:05 pm

Lunch & Exhibition

12:20 pm

45-minutes Vendor Workshop by BioSymetrics
Using Machine Learning for Mechanism of Action Prediction Following Phenotypic Screening

Session 3: Hot Targets from NYC Academic and Biotech Scene

01:20 pm

Introduction by Session Chairs

Dr Amjad ALI
MERCK & CO. INC., Kenilworth, United States
Prof. Robert DEVITA
ICAHN SCHOOL OF MEDICINE AT MT. SINAI, New York, United States

01:25 pm

Therapeutic Potential of the Gut-Brain Axis

Dr Ann WEBER
KALLYOPE, New York, United States

02:00 pm

Rational Design of Inhibitors of Protein-Protein Interactions

Prof. Paramjit ARORA
NYU, New York, United States

02:35 pm

Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd)

Dr John GINN
TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, United States

03:10 pm

Coffee Break & Exhibition

03:40 pm

Next Generation Drug Discovery

Dr Steve COLLETTI
LODO THERAPEUTICS, New York, United States

04:15 pm

Designing and Combining Cancer's Off Switches

Dr Karen AKINSANYA
SCHRODINGER, New York City, United States

04:50 pm

Free Time

07:00 pm

Poster Session & Networking

09:00 pm

End of the Day

Session 4: Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease

08:30 am

Introduction by Session Chairs

Dr Erin DIMAURO
MERCK & CO. INC., Boston, United States
Dr Hongjun David ZHANG
CEREVEL THERAPEUTICS, LLC, Boston, United States

08:35 am

Unraveling Autophagy in Cancer Using Chemical Genetics

Prof. Jeff MACKEIGAN
MICHIGAN STATE UNIVERSITY, East Lansing, United States

09:05 am

Activating PTEN-Induced Kinase 1 (PINK1) for Parkinson’s Disease

Dr Nicholas HERTZ
MITOKININ INC, San Francisco, United States

09:35 am

The Development of Substrate Competitive and Allosteric Inhibitors of Cysteine Protease ATG4B to Prevent Autophagic Flux

Dr Jason CROSS
MD ANDERSON CANCER CENTER, Houston, United States

10:05 am

Coffee Break & Exhibition

10:35 am

Discovery of Highly Potent and Selective Vacuolar Protein Sorting 34 (Vps34) Inhibitors

Dr Jenny VIKLUND
SPRINT BIOSCIENCE AB, Huddinge, Sweden

11:05 am

Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration

Prof. Evripidis GAVATHIOTIS
ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States

11:35 am

Title of talk to be confirmed

Dr Peter FULLER
MERCK & CO. INC., Boston, United States

12:05 pm

End of AM Program

01:00 pm

Social Activities & Free Time

Award Session

05:45 pm

Award Dinner

07:15 pm

Opening Address

2020 Division of Medicinal Chemistry Award

07:30 pm

2020 Division of Medicinal Chemistry Award Lecture
Title of Talk to be confirmed

Prof. Shaomeng WANG
UNIVERSITY OF MICHIGAN, Ann Arbor, United States

Introduction by Dr Scott Runyon, ACS Medi Division Chair 2020

2020 IUPAC-Richter Prize

08:15 pm

2020 IUPAC-Richter Prize Lecture
How I Spent my Summer Vacation: Insights from a 30-year Career in Drug Discovery (and Molecules that have Broken my Heart)

Dr John E. MACOR
SANOFI, Waltham, United States

Introduction by Dr Janos Fischer, Chair of the IUPAC-Richter Prize Selection Committee

09:00 pm

End of the Day

Session 5: Next Generation Therapies Shaped by Clinical Data

08:30 am

Introduction by Session Chair

Dr Matthew VOLGRAF
GENENTECH INC., South San Francisco, United States

08:35 am

3 Generations of RAF Inhibitors – Learnings and Improvements Based on Clinical Data

Dr Robert AVERSA
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States

09:05 am

LPA1 Receptor Antagonists for the Treatment of IPF

Dr Peter CHENG
BRISTOL-MYERS SQUIBB R & D, Hopewell, United States

09:35 am

Evolution of Clinical PI3K Inhibitors at Genentech

Dr Steve STABEN
GENENTECH, South San Francisco, United States

10:05 am

Coffee Break & Exhibition

10:35 am

Leveraging the Human PK of PF-06882961, an Oral Small Molecule GLP-1R Agonists, in the Discovery of a 2nd Generation Candidate

Dr David GRIFFITH
PFIZER INC., Cambridge, United States

11:05 am

Discovery of Oral CGRP Receptor Antagonists for the Treatment of Migraine: Learning from (Clinical) Experience

Dr Christopher BURGEY
MERCK & CO., INC., West Point, United States

11:35 am

Discovery of Risdiplam, a Selective SMN2 Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy

Dr Hasane RATNI
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland

12:05 pm

Lunch Break & Exhibition

12:20 pm

45-minutes Vendor Workshop by Schrödinger
Designing Molecules in 3D

Session 6: Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry

01:20 pm

Introduction by Session Chair

Dr Philip KYM
ABBVIE, North Chicago, United States

01:25 pm

Delivering Innovative Medicines: Small Changes can have a Large Effect

Dr Wendy YOUNG
GENENTECH, South San Francisco, United States

02:00 pm

Discovery of Novel Drug Regimens for the Treatment of Tuberculosis

Dr Christopher B. COOPER
TB ALLIANCE, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, New York, United States

02:35 pm

Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor

Dr Kristine E. FRANK
ABBVIE, North Chicago, United States

03:10 pm

Coffee Break & Exhibition

03:40 pm

DSM265, a Dihydroorotate Dehydrogenase Inhibitor for the Treatment of Malaria

Prof. Meg PHILLIPS
UNIVERSITY OF TEXAS SOUTHWESTERN MED CENTER, Dallas, United States

04:15 pm

Discovery of the Selective Allosteric TYK2 Inhibitor BMS-986165 for the Treatment of Autoimmune Diseases

Dr Steve WROBLESKI
BRISTOL-MYERS SQUIBB, Princeton, United States

04:50 pm

Closing Remarks

Dr Amjad ALI
MERCK & CO. INC., Kenilworth, United States
Prof. Robert DEVITA
ICAHN SCHOOL OF MEDICINE AT MT. SINAI, New York, United States

05:00 pm

Departure